Bipin N. Savani

Nov 23, 2024 | chi.scholasticahq.com | Mohamad Mohty |Bipin N. Savani

In today’s digital age, social media has become a transformative force, significantly impacting the field of medicine. While traditionally known for face-to-face consultations and academic discussions, healthcare professionals are increasingly turning to platforms like X (formerly known as Twitter), Facebook, or LinkedIn (to mention just a few) to share knowledge, collaborate, and even enhance patient care.

Jul 7, 2024 | nature.com | Mazyar Shadman |Madiha Iqbal |Nausheen Ahmed |Peter A. Riedell |Natalie Grover |Nilanjan Ghosh | +8 more

AbstractIn patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry.

Jun 14, 2024 | nature.com | Rachel Gilmore |Bhagirathbhai Dholaria |Reena V. Jayani |Bipin N. Savani |Kendall Shultes |Dwight D. Eplin

AbstractThe age effect in severe aplastic anemia (SAA) following allogeneic hematopoietic cell transplantation (HCT) favors the use of reduced intensity conditioning (RIC) regimens in older adults. We implemented a non-myeloablative regimen consisting of fludarabine, cyclophosphamide, and rituximab (FCR) to improve HCT outcomes in SAA. Patients who underwent first HCT for SAA utilizing an FCR regimen between January 2016 and May 2022 were included.

May 15, 2024 | nature.com | Trent Wang |Nausheen Ahmed |Andy Chen |Narendranath Epperla |Bradley M. Haverkos |Nasheed M. Hossain | +10 more

AbstractCD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2–9).

Mar 10, 2024 | nature.com | Rahul Shah |Bipin N. Savani |Reena V. Jayani |Bhagirathbhai Dholaria

With identical major and minor human leukocyte antigen, how did GVHD develop in patients undergoing syngeneic- or auto-HCT? Glazier et al. [4] initially demonstrated in animal transplant models that the phenomenon indistinguishable from classic acute GVHD could develop in CsA-treated and lethally irradiated rats after syngeneic or autologous BM reconstitution.